Invitrogen Corporation (Nasdaq:IVGN - News) and Cellartis AB today announced a collaboration between the companies to develop novel engineered human embryonic stem cell (hESC) reporter lines. The collaboration will bring together Invitrogen's platform technologies and expertise in molecular and cellular biology, labeling and detection and cell culture and Cellartis' expertise in deriving and growing hESC lines. These lines will, for the first time, provide scientists with a visual readout for tracking stem cell differentiation into different lineages and also enable scientists to study multiple genes involved in differentiation pathways, without having to sacrifice the cells. Financial terms of the collaboration were not disclosed.
